explore -WSS

explore

author：entertainment 2025-10-02 20:47:09 - browse：862

Jeremey Wyatt ActiGraph

As drugmakers wade into using digital health technologies, ActiGraph has made its mission to become the wearable of choice for the industry.

The Pensacola, Fla.-based company creates devices and software explicitly designed for clinical trials by focusing on features that matter to sponsors, like bulletproof reliability, access to raw sensor data, and 30-day battery life so that trial participants never have to worry about charging devices.

There are many potential advantages to using wearables in clinical trials. Continuous data may collect a more comprehensive picture of how a patient responds to treatment and could help drugmakers complete trials faster with fewer participants. But risk-averse companies have been slow to adopt the technology and opt instead for the certainty of established methods for capturing data. The industry has yet to see a drug approved with evidence from a wearable device.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Bright Health sells Medicare Advantage business to Molina
Next article： Medicare Advantage 2025 payments will dip, Biden administration says

WSS

Gut bacteria may contribute to kidney autoimmunity, study finds

FDA approves Recor Medical high blood pressure device

STAT Executive Editor Rick Berke on STAT's 8th birthday

Removing probiotics from the NICU could threaten preemies' health

Alzheimer's risk factor APOE4 may be a distinct form of the disease

UCSF medical school apologizes for unethical prisoner experiments

explore

explore

explore

Sports medicine is finally prioritizing gender equality

Senate panel clears PBM, hopsital reforms

After affirmative action ruling, medical educators look to 'holistic review'

Readout Newsletter: Biogen, Eisai, Aardvark Therapeutics, etc.

The cancer drug shortage isn’t new — and neither are the solutions

Biotech incubator Curie.Bio graduates its first startup

Jerome Adams on the need for new antivirals for Covid

AstraZeneca CEO says participant had neurological symptoms, could be discharged today

Jerome Adams on the need for new antivirals for Covid

Oral obesity drug from Viking Therapeutics hits key early target

hotspot

A clever new way to fix Medicaid and graduate medical education

Covid silver lining: Unprecedented look at human immune system

Gut bacteria may contribute to kidney autoimmunity, study finds

Insurer loopholes limit power of law against surprise medical bills

FDA approves Recor Medical high blood pressure device

AstraZeneca CEO says participant had neurological symptoms, could be discharged today

entertainment

hotspot

knowledge

explore